Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.51 |
| ▸ | RELA | Q04206 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL626575 | 0.86 | MEN1 (0.64) | MEN1KMT2AMAPK10GFERSMN1; SMN2 | |
| SCHEMBL29582475 | 0.86 | MEN1 (0.64) | MEN1KMT2AMAPK10GFERSMN1; SMN2 | |
| SCHEMBL31138002 | 0.84 | MEN1 (0.61) | MEN1KMT2AMAPK10GFERSMN1; SMN2 | |
| SCHEMBL31390266 | 0.83 | MEN1 (0.59) | MEN1KMT2AMAPK10GFERSMN1; SMN2 | |
| SCHEMBL221242 | 0.81 | KMT2A (0.76) | MEN1KMT2AMAPK10GFERLMNA | |
| SCHEMBL29391624 | 0.81 | KMT2A (0.76) | MEN1KMT2AMAPK10GFERLMNA | |
| SCHEMBL25956607 | 0.81 | CTSD (0.58) | MEN1KMT2AMAPK10GFERLMNA | |
| SCHEMBL904444 | 0.79 | NPC1 (0.60) | MEN1KMT2AMAPK10GFERSMN1; SMN2 | |
| SCHEMBL904463 | 0.79 | MEN1 (0.55) | MEN1KMT2AMAPK10GFERSMN1; SMN2 | |
| SCHEMBL21258999 | 0.79 | NPC1 (0.60) | MEN1KMT2AMAPK10GFERLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709637-B2 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | BASF SE (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070088026-A1 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | METAVANTE CORPORATION | 2007-04-19 | — | — | US | disclosed |
| US-20060293503-A1 | Polyaminopyridines and method for producing same | SUMITOMO SEIKA CHEMICALS CO., LTD (JP) | 2006-12-28 | — | — | US | disclosed |
| US-7153860-B2 | 5-Phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi | BASF AKTIENGESELLSCHAFT (DE) | 2006-12-26 | — | — | US | disclosed |
| EP-1669390-A1 | POLYAMINOPYRIDINES AND METHOD FOR PRODUCING SAME | SUMITOMO SEIKA CHEMICALS CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
| US-20040116429-A1 | 5-Phenylpyrimidines, methods and intermediate products for the production thereof and use of the same for controlling pathogenic fungi | BASF SE (DE) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088026-A1 | 5-phenylpyrimidines, their preparation, intermediates for their preparation, and their use for controlling harmful fungi | DPYD, CBR3, RNGTT | MEN1 4508/4885KMT2A 3289/4885MAPK10 4028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.